Healthcare technology and technology assessment |
| |
Authors: | James H. Herndon Raymond Hwang K. J. Bozic |
| |
Affiliation: | (1) Department of Orthopaedic Surgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 617-367-5117, USA;(2) Department of Orthopaedic Surgery and Institute for Health Policy Studies, School of Medicine, University of California, San Francisco, CA, USA |
| |
Abstract: | New technology is one of the primary drivers for increased healthcare costs in the United States. Both physician and industry play important roles in the development, adoption, utilization and choice of new technologies. The Federal Drug Administration regulates new drugs and new medical devices, but healthcare technology assessment remains limited. Healthcare technology assessment originated in federal agencies; today it is decentralized with increasing private sector efforts. Innovation is left to free market forces, including direct to consumer marketing and consumer choice. But to be fair to the consumer, he/she must have free knowledge of all the risks and benefits of a new technology in order to make an informed choice. Physicians, institutions and industry need to work together by providing proven, safe, clinically effective and cost effective new technologies, which require valid pre-market clinical trials and post-market continued surveillance with national and international registries allowing full transparency of new products to the consumer—the patient. No grant support. An erratum to this article can be found at |
| |
Keywords: | Technology Assessment Costs Clinical trials |
本文献已被 SpringerLink 等数据库收录! |
|